Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
US8334282B2 · kind B2 · utility
7Cited by
2References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2010 |
| Grant date | Dec 18, 2012 |
| Priority date | — |
| Expiry date | Jul 6, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel substituted amino-azetidines that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, hepatic disorders, and a combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.